We are skilled at finding senior executives and experts, renowned scientists, clinicians and researchers worldwide, and assessing them from both a leadership and scientific perspective.
Whether you are a start-up, an established corporation, or a CDMO, working on pre-clinical or clinical development, or commercialisation, we’ll help you build collaborative teams. We are skilled in customising our approach to attract diverse, globally-experienced leaders for science-driven environments.
New business models require collaborative approaches to pipeline innovation, manufacturing and supply, and myriad bench-to-bedside translations. This matrix of layered initiatives requires leaders at all levels of the organisation to be capable of cutting across traditional disciplines through influence, persuasion and compromise.
Global patient demographics, emerging market demands and opportunities, and an increasingly female talent pool require inclusive leadership. Business leaders must become adept at recognising and prioritising the importance of diversity to harness its advantages for business and society.
When it comes to sustainability, we aspire to the same standards as our clients. We are proud to have been awarded a Bronze rating by Ecovadis in 2022.
Big data collection and usage; digitalization; and artificial intelligence in the entire life-cycle of therapies, from development to the point of patient access, are unstoppable trends. Wielding these technology tools in a meaningful way requires innovation leadership that is balanced by well-defined change management skills and a keen ability to prioritise.
Global patient demographics, emerging market demands and opportunities, and an increasingly female talent pool require inclusive leadership. Business leaders must become adept at recognising and prioritising the importance of diversity to harness its advantages for business and society.
When it comes to sustainability, we aspire to the same standards as our clients. We are proud to have been awarded a Bronze rating by Ecovadis in 2022.
GSK has gained US Food and Drug Administration (FDA) breakthrough therapy designation (BTD) for its B7-H3-targeted antibody-drug conjugate (ADC), GSK’227, to treat adults with relapsed or refractory osteosarcoma who have progressed on a minimum of two previous lines of therapy.
As part of its long-term plans in the country, US drugmaker Merck & Co., operating as MSD outside of North America, has acquired WuXi Biologics’ site in Dundalk, Ireland, for about $500 million. The deal was announced through Ireland’s Foreign Direct Investment Agency (IDA) and MSD’s Ireland unit.
Galapagos, a biotechnology company headquartered in Belgium, plans to split into two entities: a newly formed company (name to be announced at a later date) that will focus on building a pipeline of innovative drugs through transformative transactions, and Galapagos, which will continue to develop its cell therapy manufacturing platform in oncology.
